jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Ovarian cyst Biopsy - XL

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histopathology of ovarian lesions.

₹888₹1,269

30% OFF

Ovarian Cyst Biopsy - XL: Comprehensive Medical Test Information Guide

  • Why is it done?
    • Definitive tissue diagnosis of ovarian cysts to determine benign vs. malignant pathology
    • Evaluation of complex or indeterminate ovarian masses that are inconclusive on imaging (ultrasound, MRI, or CT)
    • Assessment of cyst size greater than 3-4 cm with suspicious imaging features or elevated tumor markers
    • Detection of ovarian cancer or other malignancies in high-risk patients with family history or BRCA mutations
    • Characterization of cystic lesions with growth on serial imaging or associated with pain, bleeding, or rupture risk
    • Investigation of persistent pelvic masses in postmenopausal women with borderline elevated CA-125 levels
    • Typical timing: Performed when imaging findings are suspicious or indeterminate, typically after initial imaging workup and risk stratification
  • Normal Range
    • Normal/Negative Result: Benign cyst with histopathological findings consistent with simple serous cyst, mucinous cyst, mature cystic teratoma (dermoid cyst), or corpus luteum cyst
    • Benign lesions show normal epithelial cells without atypia, normal mitotic figures, absence of necrosis, and no invasion into surrounding stroma
    • Borderline/Atypical Results: Low malignant potential tumors (LMP) with proliferation of epithelial cells but without frank invasion; may show areas of atypia or increased mitotic activity
    • Positive/Abnormal Result: Malignant cells present with evidence of epithelial ovarian cancer, germ cell tumors, sex cord-stromal tumors, or metastatic disease
    • Malignant findings include nuclear atypia, high mitotic rate, tumor necrosis, stromal invasion, and architectural disorganization
    • Classification: Results are reported with histological type (serous, mucinous, clear cell, endometrioid, mixed) and grade (G1, G2, G3 for malignant lesions)
  • Interpretation
    • Benign Findings: Indicate a functional or simple cyst requiring no treatment or routine surveillance; patients can typically be reassured with conservative management
    • Borderline Malignant Potential (BMP) Tumors: Require careful monitoring and often consultation with gynecologic oncology; clinical outcomes are generally favorable compared to invasive carcinoma, but recurrence risk exists in 10-30% of cases
    • Stage I Epithelial Ovarian Cancer: Tumor confined to ovary/ovaries; grade and histological type determine prognosis and treatment decisions (observation vs. chemotherapy)
    • Advanced Stage Disease: Indicates spread beyond ovaries; requires comprehensive staging studies (CT/MRI chest/abdomen/pelvis) and aggressive multimodal treatment
    • Factors affecting interpretation: Biopsy location adequacy, specimen handling, immunohistochemical staining results, molecular testing (BRCA status, microsatellite instability, tumor mutational burden)
    • Clinical significance: Histological diagnosis guides treatment planning, predicts prognosis, determines eligibility for targeted therapies, and establishes surveillance protocols
    • Specimen adequacy issues: Insufficient tissue, poor preservation, or contamination may necessitate repeat biopsy for definitive diagnosis
  • Associated Organs
    • Primary Organ System: Reproductive system, specifically the ovaries; also involves the peritoneum, fallopian tubes, and uterus in advanced disease
    • Common Benign Conditions: Follicular cysts, corpus luteum cysts, theca lutein cysts, paraovarian cysts, and functional cysts related to menstrual cycle
    • Associated Benign Neoplasms: Mature cystic teratomas (dermoid cysts), serous cystadenomas, mucinous cystadenomas, and ovarian fibromas
    • Malignant Conditions: Epithelial ovarian cancer (serous, mucinous, clear cell, endometrioid carcinoma), germ cell tumors (dysgerminoma, yolk sac tumor), sex cord-stromal tumors (granulosa cell tumor)
    • Associated Metastatic Disease: Metastases from stomach (Krukenberg tumors), colon, breast, pancreas, or appendix involving ovary
    • Potential Complications: Ovarian torsion, hemorrhage into cyst, cyst rupture causing peritonitis, infection, and acute pelvic pain requiring emergency intervention
    • Cancer Spread Patterns: Epithelial ovarian cancer may spread to peritoneum, omentum, other abdominal/pelvic organs, lymph nodes, and eventually liver or lungs
  • Follow-up Tests
    • If Benign Pathology: Pelvic ultrasound at 3-6 months, then annually for 5 years to confirm stability; serum CA-125, inhibin A/B if indicated
    • If Borderline Malignant Potential: CT/MRI chest/abdomen/pelvis for comprehensive staging; serum tumor markers (CA-125, CEA); gynecologic oncology consultation
    • If Ovarian Cancer Diagnosed: Full staging workup with CT/MRI imaging, chest X-ray, tumor markers (CA-125, HE4), and possibly exploratory laparoscopy/laparotomy
    • Molecular and Genetic Testing: BRCA1/BRCA2 mutation testing, microsatellite instability (MSI), mismatch repair deficiency (MMR), PD-L1 expression status
    • Tumor Markers: Serial CA-125 monitoring every 3 months post-treatment, or HE4 (Human Epididymis Protein 4) for surveillance
    • Imaging Surveillance: Pelvic ultrasound or MRI every 3-6 months during treatment; CT imaging if rise in tumor markers or clinical symptoms
    • Complementary Tests: Transvaginal ultrasound, diagnostic laparoscopy, paracentesis if ascites present, liver biopsy if hepatic metastases suspected
    • Long-term Surveillance: Clinical examination every 2-3 months for 2 years, then 3-6 months for 3 years; annual thereafter for patients with early-stage disease
  • Fasting Required?
    • Fasting Required: No - Ovarian cyst biopsy does not require fasting as it is a tissue sampling procedure performed under imaging guidance (ultrasound or CT)
    • NPO Status: If procedure performed under general anesthesia or conscious sedation, standard NPO guidelines apply - typically 6-8 hours before procedure (no food/liquids)
    • Medications: Continue routine medications unless otherwise directed; discuss anticoagulants, aspirin, NSAIDs, or blood thinners with interventional radiologist (may need temporary cessation 3-5 days before)
    • Pre-procedure Preparation: Schedule test in first 10 days of menstrual cycle if possible; empty bladder and bowel before procedure; wear comfortable, easily removable clothing
    • Contrast Considerations: If contrast-enhanced imaging used, verify renal function (creatinine, eGFR) prior to procedure; maintain adequate hydration before and after
    • Documentation: Bring photo ID, insurance card, previous imaging results, and allergy information; sign informed consent acknowledging risks (bleeding, infection, bowel perforation)
    • Post-procedure: May experience mild cramping or spotting; rest for 24 hours; avoid strenuous activity/heavy lifting for 1 week; report severe pain, heavy bleeding, or fever to physician

How our test process works!

customers
customers